The Filings Report

DexCom

DXCMNasdaqCIK 1093557Healthcare / Medical Devicesfiscal year ends December67 quarters since 2010

Revenue, Q3 FY2026
$1.3B
+11.2% on Q3 FY2025
Net income
$275M
−3.1% on Q3 FY2025
Free cash flow
$273M
−52.9% on Q3 FY2025
Diluted EPS
$0.72
+2.9% on Q3 FY2025
Revenue, TTM
$5.1B
trailing four quarters
Net margin, TTM
19.4%
net income $991M
Free cash flow, TTM
$1.1B
$1.4B less $316M capex
Cash and equivalents
$961M
long-term debt —, Sep 30, 2026
Shares, 12-month change
−4.4%
373M shares, Sep 30, 2026
Buybacks, TTM
—
no yield
Dividends, TTM
—
no yield
Market value
$30.7B
at the close, buybacks

Latest quarter Q3 FY2026, filed October 29, 2026. Trailing figures sum the latest four quarters. Market values at the latest close, from a market data vendor.

In Q3 FY2026, the quarter ended September 30, 2026, DexCom reported revenue of $1.3B, +11.2% on Q3 FY2025, and net income of $275M (−3.1%). Operating margin was 24.3%. Free cash flow, operating cash flow less capital expenditures, was $273M ($326M less $53M). Diluted earnings per share were $0.72.

The last 16 quarters

Q4 FY2022 to Q3 FY2026, through the filing of October 29, 2026.

Revenue and net incomeRevenueNet income
$0$500M$1.0B$1.5BQ4'22, Revenue: $815MQ4'22, Net income: $92MQ4'22Q1'23, Revenue: $742MQ1'23, Net income: $49MQ1'23Q2'23, Revenue: $871MQ2'23, Net income: $116MQ2'23Q3'23, Revenue: $975MQ3'23, Net income: $121MQ3'23Q4'23, Revenue: $1.0BQ4'23, Net income: $256MQ4'23Q1'24, Revenue: $921MQ1'24, Net income: $146MQ1'24Q2'24, Revenue: $1.0BQ2'24, Net income: $144MQ2'24Q3'24, Revenue: $994MQ3'24, Net income: $135MQ3'24Q4'24, Revenue: $1.1BQ4'24, Net income: $152MQ4'24Q1'25, Revenue: $1.0BQ1'25, Net income: $105MQ1'25Q2'25, Revenue: $1.2BQ2'25, Net income: $180MQ2'25Q3'25, Revenue: $1.2BQ3'25, Net income: $284MQ3'25Q4'25, Revenue: $1.3BQ4'25, Net income: $267MQ4'25Q1'26, Revenue: $1.2BQ1'26, Net income: $200MQ1'26Q2'26, Revenue: $1.3BQ2'26, Net income: $249MQ2'26Q3'26, Revenue: $1.3BQ3'26, Net income: $275MQ3'26$0$500M$1.0B$1.5BQ4'22, Revenue: $815MQ4'22, Net income: $92MQ1'23, Revenue: $742MQ1'23, Net income: $49MQ1'23Q2'23, Revenue: $871MQ2'23, Net income: $116MQ3'23, Revenue: $975MQ3'23, Net income: $121MQ3'23Q4'23, Revenue: $1.0BQ4'23, Net income: $256MQ1'24, Revenue: $921MQ1'24, Net income: $146MQ1'24Q2'24, Revenue: $1.0BQ2'24, Net income: $144MQ3'24, Revenue: $994MQ3'24, Net income: $135MQ3'24Q4'24, Revenue: $1.1BQ4'24, Net income: $152MQ1'25, Revenue: $1.0BQ1'25, Net income: $105MQ1'25Q2'25, Revenue: $1.2BQ2'25, Net income: $180MQ3'25, Revenue: $1.2BQ3'25, Net income: $284MQ3'25Q4'25, Revenue: $1.3BQ4'25, Net income: $267MQ1'26, Revenue: $1.2BQ1'26, Net income: $200MQ1'26Q2'26, Revenue: $1.3BQ2'26, Net income: $249MQ3'26, Revenue: $1.3BQ3'26, Net income: $275MQ3'26

Net income losses drawn in red.

Free cash flow
$0$200M$400M$600MQ4'22, Free cash flow: $69MQ4'22Q1'23, Free cash flow: $81MQ1'23Q2'23, Free cash flow: $131MQ2'23Q3'23, Free cash flow: $219MQ3'23Q4'23, Free cash flow: $81MQ4'23Q1'24, Free cash flow: $152MQ1'24Q2'24, Free cash flow: $213MQ2'24Q3'24, Free cash flow: $88MQ3'24Q4'24, Free cash flow: $177MQ4'24Q1'25, Free cash flow: $97MQ1'25Q2'25, Free cash flow: $209MQ2'25Q3'25, Free cash flow: $579MQ3'25Q4'25, Free cash flow: $192MQ4'25Q1'26, Free cash flow: $449MQ1'26Q2'26, Free cash flow: $185MQ2'26Q3'26, Free cash flow: $273MQ3'26$0$200M$400M$600MQ4'22, Free cash flow: $69MQ1'23, Free cash flow: $81MQ1'23Q2'23, Free cash flow: $131MQ3'23, Free cash flow: $219MQ3'23Q4'23, Free cash flow: $81MQ1'24, Free cash flow: $152MQ1'24Q2'24, Free cash flow: $213MQ3'24, Free cash flow: $88MQ3'24Q4'24, Free cash flow: $177MQ1'25, Free cash flow: $97MQ1'25Q2'25, Free cash flow: $209MQ3'25, Free cash flow: $579MQ3'25Q4'25, Free cash flow: $192MQ1'26, Free cash flow: $449MQ1'26Q2'26, Free cash flow: $185MQ3'26, Free cash flow: $273MQ3'26

Operating cash flow less capital expenditures; negative quarters in red.

Cash and equivalents against long-term debtCash and equivalentsLong-term debt
$0$500M$1.0B$1.5B$2.0BQ4'22, Cash and equivalents: $642MQ4'22Q1'23, Cash and equivalents: $623MQ1'23Q2'23, Cash and equivalents: $1.2BQ2'23Q3'23, Cash and equivalents: $644MQ3'23Q4'23, Cash and equivalents: $566MQ4'23Q1'24, Cash and equivalents: $851MQ1'24Q2'24, Cash and equivalents: $939MQ2'24Q3'24, Cash and equivalents: $621MQ3'24Q4'24, Cash and equivalents: $606MQ4'24Q1'25, Cash and equivalents: $905MQ1'25Q2'25, Cash and equivalents: $1.2BQ2'25Q3'25, Cash and equivalents: $1.8BQ3'25Q4'25, Cash and equivalents: $918MQ4'25Q1'26, Cash and equivalents: $1.1BQ1'26Q2'26, Cash and equivalents: $1.1BQ2'26Q3'26, Cash and equivalents: $961MQ3'26$0$500M$1.0B$1.5B$2.0BQ4'22, Cash and equivalents: $642MQ1'23, Cash and equivalents: $623MQ1'23Q2'23, Cash and equivalents: $1.2BQ3'23, Cash and equivalents: $644MQ3'23Q4'23, Cash and equivalents: $566MQ1'24, Cash and equivalents: $851MQ1'24Q2'24, Cash and equivalents: $939MQ3'24, Cash and equivalents: $621MQ3'24Q4'24, Cash and equivalents: $606MQ1'25, Cash and equivalents: $905MQ1'25Q2'25, Cash and equivalents: $1.2BQ3'25, Cash and equivalents: $1.8BQ3'25Q4'25, Cash and equivalents: $918MQ1'26, Cash and equivalents: $1.1BQ1'26Q2'26, Cash and equivalents: $1.1BQ3'26, Cash and equivalents: $961MQ3'26

Positions at each quarter end, as filed; short-term investments are not included.

Income statement

Last eight quarters, newest first, through Q3 FY2026 filed October 29, 2026.

DexCom income statement, quarterly
Millions of dollarsQ3 FY2026ended Sep 30, 2026filed Oct 29, 2026Q2 FY2026ended Jun 30, 2026filed Jul 30, 2026Q1 FY2026ended Mar 31, 2026filed Apr 30, 2026Q4 FY2025ended Dec 31, 2025filed Feb 12, 2026Q3 FY2025ended Sep 30, 2025filed Oct 30, 2025Q2 FY2025ended Jun 30, 2025filed Jul 30, 2025Q1 FY2025ended Mar 31, 2025filed May 1, 2025Q4 FY2024ended Dec 31, 2024filed Feb 18, 2025YoYQ3 FY2026vs Q3 FY2025
Revenue1,3451,3081,1921,2601,2091,1571,0361,114+11.2%
Cost of revenue480478442467478468447458+0.5%
Gross profit864830750793731689589656+18.2%
Research and development162153145148158148145140+2.6%
Selling, general and administrative376359350322331328310327+13.3%
Operating income327318255323243213134189+34.9%
Other income (expense)8(1)1418110292122−93.2%
Pretax income335318270341352241154211−5.0%
Income tax6068707369614960−13.0%
Net income275249200267284180105152−3.1%
Diluted EPS ($)0.720.640.51—0.700.450.27—+2.9%
Diluted shares (millions)384390394—407408408——

Fourth quarters are the fiscal year less the first nine months when the filer reports no discrete fourth quarter, and are marked. Diluted EPS is never derived, so a derived quarter shows none. Italic figures are derived.

Balance sheet

Last eight quarters, newest first, through Q3 FY2026 filed October 29, 2026.

DexCom balance sheet, quarterly
Millions of dollarsQ3 FY2026ended Sep 30, 2026filed Oct 29, 2026Q2 FY2026ended Jun 30, 2026filed Jul 30, 2026Q1 FY2026ended Mar 31, 2026filed Apr 30, 2026Q4 FY2025ended Dec 31, 2025filed Feb 12, 2026Q3 FY2025ended Sep 30, 2025filed Oct 30, 2025Q2 FY2025ended Jun 30, 2025filed Jul 30, 2025Q1 FY2025ended Mar 31, 2025filed May 1, 2025Q4 FY2024ended Dec 31, 2024filed Feb 18, 2025YoYQ3 FY2026vs Q3 FY2025
Cash and equivalents9611,1051,1189181,8361,159905606−47.6%
Short-term investments——————1,5601,730—
Total current assets3,9164,0874,3324,0335,2205,0304,5544,301−25.0%
Total assets6,2396,4556,6336,3407,5007,3276,7526,485−16.8%
Total current liabilities2,2532,3582,2242,1433,3363,3093,0372,932−32.5%
Long-term debt—————————
Total liabilities3,7033,8343,6763,5944,7744,7544,4854,382−22.4%
Stockholders’ equity2,5352,6212,9572,7462,7262,5732,2672,103−7.0%
Shares outstanding (millions)373377386385390392392391—

Positions at each period end. Nothing on this statement is derived. Long-term debt is the filed noncurrent line only; no total-debt composite is constructed across filers. Italic figures are derived.

Cash flow statement

Last eight quarters, newest first, through Q3 FY2026 filed October 29, 2026.

DexCom cash flow statement, quarterly
Millions of dollarsQ3 FY2026ended Sep 30, 2026filed Oct 29, 2026Q2 FY2026ended Jun 30, 2026filed Jul 30, 2026Q1 FY2026ended Mar 31, 2026filed Apr 30, 2026Q4 FY2025ended Dec 31, 2025filed Feb 12, 2026Q3 FY2025ended Sep 30, 2025filed Oct 30, 2025Q2 FY2025ended Jun 30, 2025filed Jul 30, 2025Q1 FY2025ended Mar 31, 2025filed May 1, 2025Q4 FY2024ended Dec 31, 2024filed Feb 18, 2025YoYQ3 FY2026vs Q3 FY2025
Operating cash flow326269526294660303184301−50.7%
Capital expenditures538577102819487125−34.3%
Free cash flow (CFO − capex)27318544919257920997177−52.9%
Depreciation and amortization7568676564636058+17.1%
Share repurchases400——313187——0+113.7%
Dividends paid—————————

10-Qs file cash flows as year-to-date totals, so quarterly figures are differenced from consecutive filings and marked. Free cash flow is operating cash flow less capital expenditures, computed from the two filed lines. Italic figures are derived.

Annual statements

Every fiscal year filed, newest first, through FY2025 filed February 12, 2026.

Income statement

DexCom income statement, annual
Millions of dollarsFY2025ended Dec 31, 2025filed Feb 12, 2026FY2024ended Dec 31, 2024filed Feb 18, 2025FY2023ended Dec 31, 2023filed Feb 8, 2024FY2022ended Dec 31, 2022filed Feb 9, 2023FY2021ended Dec 31, 2021filed Feb 14, 2022FY2020ended Dec 31, 2020filed Feb 11, 2021FY2019ended Dec 31, 2019filed Feb 13, 2020FY2018ended Dec 31, 2018filed Feb 21, 2019FY2017ended Dec 31, 2017filed Feb 27, 2018FY2016ended Dec 31, 2016filed Feb 28, 2017FY2015ended Dec 31, 2015filed Feb 23, 2016FY2014ended Dec 31, 2014filed Feb 25, 2015FY2013ended Dec 31, 2013filed Feb 20, 2014FY2012ended Dec 31, 2012filed Feb 21, 2013FY2011ended Dec 31, 2011filed Feb 23, 2012FY2010ended Dec 31, 2010filed Aug 3, 2011FY2009ended Dec 31, 2009filed Aug 3, 2011
Revenue4,6624,0333,6222,9102,4491,9271,4761,032719573402259160100764930
Cost of revenue1,8601,5951,3331,027768647545368226195124836053403026
Gross profit2,8022,4382,2891,8831,6811,2809326644923782781761004736184
Research and development599552506484517360274200185156138694538302314
Selling, general and administrative1,2911,2861,1851,0088116185164333492861981288464514135
Operating income912600598391266300142(186)(42)(64)(57)(21)(29)(56)(45)(45)(46)
Other income (expense)1771091130(9)162627(1)00——000
Pretax income1,088709710391257298104(126)(49)(65)(57)(22)(30)(56)(45)(55)—
Income tax2521331695040(252)3121000(1)00—
Net income836576542341217550101(127)(50)(66)(58)(22)(30)(54)(45)(55)(54)
Diluted EPS ($)2.091.421.300.820.531.330.28*(0.36)*(0.14)*————————
Diluted shares (millions)406413426428429420369*353*345*————————

Balance sheet

DexCom balance sheet, annual
Millions of dollarsFY2025ended Dec 31, 2025filed Feb 12, 2026FY2024ended Dec 31, 2024filed Feb 18, 2025FY2023ended Dec 31, 2023filed Feb 8, 2024FY2022ended Dec 31, 2022filed Feb 9, 2023FY2021ended Dec 31, 2021filed Feb 14, 2022FY2020ended Dec 31, 2020filed Feb 11, 2021FY2019ended Dec 31, 2019filed Feb 13, 2020FY2018ended Dec 31, 2018filed Feb 21, 2019FY2017ended Dec 31, 2017filed Feb 27, 2018FY2016ended Dec 31, 2016filed Feb 28, 2017FY2015ended Dec 31, 2015filed Feb 23, 2016FY2014ended Dec 31, 2014filed Feb 25, 2015FY2013ended Dec 31, 2013filed Feb 20, 2014FY2012ended Dec 31, 2012filed Feb 21, 2013FY2011ended Dec 31, 2011filed Feb 23, 2012FY2010ended Dec 31, 2010filed Aug 3, 2011FY2009ended Dec 31, 2009filed Aug 3, 2011
Cash and equivalents9186065666421,0538184461,137442958672438354
Short-term investments—1,7302,1601,8101,360——9310729291211417942—
Total current assets4,0334,3014,4263,6693,6843,4251,9691,700745280231146937810565—
Total assets6,3406,4856,2655,3924,9334,2912,3951,91690440329218512310612177—
Total current liabilities2,1432,9321,5561,839721614360222139102674132201515—
Long-term debt———————————577———
Total liabilities3,5944,3824,1963,2602,8912,4641,5121,253485119714438291616—
Stockholders’ equity2,7462,1032,0692,1322,0421,552883663—————————
Shares outstanding (millions)385391386386388*385*366*360*348*339*327*310*291*278*271*——

Cash flow statement

DexCom cash flow statement, annual
Millions of dollarsFY2025ended Dec 31, 2025filed Feb 12, 2026FY2024ended Dec 31, 2024filed Feb 18, 2025FY2023ended Dec 31, 2023filed Feb 8, 2024FY2022ended Dec 31, 2022filed Feb 9, 2023FY2021ended Dec 31, 2021filed Feb 14, 2022FY2020ended Dec 31, 2020filed Feb 11, 2021FY2019ended Dec 31, 2019filed Feb 13, 2020FY2018ended Dec 31, 2018filed Feb 21, 2019FY2017ended Dec 31, 2017filed Feb 27, 2018FY2016ended Dec 31, 2016filed Feb 28, 2017FY2015ended Dec 31, 2015filed Feb 23, 2016FY2014ended Dec 31, 2014filed Feb 25, 2015FY2013ended Dec 31, 2013filed Feb 20, 2014FY2012ended Dec 31, 2012filed Feb 21, 2013FY2011ended Dec 31, 2011filed Feb 23, 2012FY2010ended Dec 31, 2010filed Aug 3, 2011FY2009ended Dec 31, 2009filed Aug 3, 2011
Operating cash flow1,441990749670443476315123925649242(33)(30)(43)(39)
Capital expenditures3643592373653891991806766563316810873
Free cash flow (CFO − capex)1,0776315123055327713556261167(5)(43)(38)(50)(42)
Depreciation and amortization252218186156102674929161511877422
Share repurchases50075068955800010000———————
Dividends paid—————————————————

Insider activity

Form 4 filings by officers, directors and 10% owners, November 1, 2024 to November 1, 2026. Only open-market purchases and sales count as buys and sells; awards, exercises, tax withholding and gifts are listed in grey and never counted.

Bought, three months
$0
0 purchases by 0 insiders; officers and directors $0
Sold, three months
$5M
14 sales by 7 insiders; officers and directors $5M
Bought, twelve months
$1M
2 purchases by 1 insider; officers and directors $1M
Sold, twelve months
$13M
32 sales by 9 insiders; officers and directors $13M

The last 25 transactions

TradedInsiderRoleTransactionSharesPriceValueHeld afterFiled
Oct 27, 2026Stern SadieEVP Chief People & Culture Offopen-market sale10b5-12,565$78.62$202K120,913Oct 28, 2026
Oct 15, 2026Brown Michael JonEVP Chief Legal Compliance Offopen-market sale10b5-11,700$85.48$145K98,185Oct 19, 2026
Sep 28, 2026Stern SadieEVP Chief People & Culture Offopen-market sale10b5-12,565$86.15$221K123,478Sep 30, 2026
Sep 15, 2026Augustinos NicholasDirectoropen-market sale10b5-1indirect6,539$84.04$550K29,293Sep 16, 2026
Sep 15, 2026Brown Michael JonEVP Chief Legal Compliance Offopen-market sale10b5-11,700$84.04$143K99,885Sep 16, 2026
Sep 14, 2026Augustinos NicholasDirectoropen-market sale10b5-1indirect1,550$84.02$130K35,832Sep 16, 2026
Sep 10, 2026Sylvain Jereme MEVP, Chief Financal Officeropen-market sale10b5-13,638$83.27$303K146,828Sep 14, 2026
Sep 10, 2026Boehnlein Glenn SDirectoraward5,841$0.00—5,841Sep 10, 2026
Aug 27, 2026Stern SadieEVP Chief People & Culture Offopen-market sale10b5-12,565$88.37$227K126,043Aug 28, 2026
Aug 22, 2026Leach Jacob StevenPresident, CEO, and Director, Directortax withholding1,451$92.34$134K418,908Aug 25, 2026
Aug 22, 2026Sylvain Jereme MEVP, Chief Financal Officertax withholding1,451$92.34$134K150,390Aug 25, 2026
Aug 22, 2026Brown Michael JonEVP Chief Legal Compliance Offtax withholding1,451$92.34$134K101,502Aug 25, 2026
Aug 22, 2026Stern SadieEVP Chief People & Culture Offtax withholding1,451$92.34$134K128,608Aug 25, 2026
Aug 20, 2026Sayer Kevin RExecutive Chair, Directoropen-market sale10b5-119,308$89.71$2M309,662Aug 24, 2026
Aug 20, 2026Sayer Kevin RExecutive Chair, Directoropen-market sale10b5-17,351$90.78$667K302,311Aug 24, 2026
Aug 20, 2026Sayer Kevin RExecutive Chair, Directoropen-market sale10b5-197$91.41$9K302,214Aug 24, 2026
Aug 14, 2026Brown Michael JonEVP Chief Legal Compliance Offopen-market sale10b5-11,700$91.93$156K102,953Aug 17, 2026
Aug 12, 2026Augustinos NicholasDirectorgiftindirect1,075$0.00—37,382Aug 13, 2026
Aug 12, 2026Heller Bridgette PDirectoropen-market sale10b5-11,012$88.29$89K29,570Aug 13, 2026
Aug 3, 2026Foletta Mark GDirectoropen-market sale10b5-1indirect2,000$85.32$171K48,852Aug 4, 2026
Jul 31, 2026Foletta Mark GDirectoropen-market sale10b5-1indirect2,000$80.00$160K50,852Aug 4, 2026
Jul 20, 2026Sayer Kevin RExecutive Chair, Directoropen-market sale10b5-126,756$76.32$2M328,970Jul 21, 2026
Jul 15, 2026Brown Michael JonEVP Chief Legal Compliance Offopen-market sale10b5-11,700$74.42$127K104,653Jul 16, 2026
Jul 6, 2026Sayer Kevin RExecutive Chair, Directoropen-market sale10b5-126,756$72.00$2M355,726Jul 7, 2026
Jun 15, 2026Brown Michael JonEVP Chief Legal Compliance Offopen-market sale10b5-11,700$75.55$128K106,353Jun 17, 2026

Full insider history for DexCom, or insider activity across all companies. A record of filings, not a recommendation.

Tracked funds holding it

1 of the tracked managers held DXCM in their latest 13F filing, through August 14, 2026. Weight is the share of the fund’s reported portfolio. How the funds have traded DXCM by quarter.

FundManagerQuarterValueSharesWeightMove
Baron Capital GroupRon BaronQ2 2026$17M245,0000.02%added +1.7%

Sources

Fiscal year ends in month 12; periods are labeled with the issuer's own fiscal calendar. Values are as most recently filed (restatements apply; per-share values are on current split basis per the connector's split table, flagged in adjusted). Flow items flagged in `derived` were computed (Q4 = FY − nine months; quarterly cash flow differenced from year-to-date filings) rather than read from a filing. `reconciliation.repaired` lists periods where a full-year figure was filed in a quarter slot: that row was dropped and the quarter rebuilt from the annual figure. `reconciliation.quarantined` lists periods where four filed quarters do not sum to the filed year — those quarterly values are withheld, so a blank there is a withholding rather than an absence of reporting.

Filer
DEXCOM, INC., CIK 1093557 on EDGAR
Extract generated
October 30, 2026
Withheld
1 line-years whose four quarters do not sum to the filed year: income tax FY2017
Repaired
2 quarters where a full-year figure was filed in a quarter slot and the quarter was rebuilt: operating income FY2017, pretax income FY2017
XBRL concepts behind each line

Income statement

Revenue: RevenueFromContractWithCustomerExcludingAssessedTax, Revenues, SalesRevenueNet
Cost of revenue: CostOfGoodsAndServicesSold, CostOfRevenue
Gross profit: GrossProfit
Research and development: ResearchAndDevelopmentExpense
Selling, general and administrative: SellingGeneralAndAdministrativeExpense
Operating income: OperatingIncomeLoss
Other income (expense): OtherNonoperatingIncomeExpense
Pretax income: IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest, IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
Income tax: IncomeTaxExpenseBenefit
Net income: NetIncomeLoss
Diluted EPS ($): EarningsPerShareDiluted
Diluted shares (millions): WeightedAverageNumberOfDilutedSharesOutstanding

Balance sheet

Cash and equivalents: CashAndCashEquivalentsAtCarryingValue
Short-term investments: AvailableForSaleSecuritiesDebtSecuritiesCurrent
Total current assets: AssetsCurrent
Total assets: Assets
Total current liabilities: LiabilitiesCurrent
Long-term debt: LongTermDebt
Total liabilities: Liabilities
Stockholders’ equity: StockholdersEquity
Shares outstanding (millions): dei:EntityCommonStockSharesOutstanding

Cash flow statement

Operating cash flow: NetCashProvidedByUsedInOperatingActivities
Capital expenditures: PaymentsToAcquirePropertyPlantAndEquipment
Free cash flow (CFO − capex): not filed
Depreciation and amortization: DepreciationDepletionAndAmortization
Share repurchases: PaymentsForRepurchaseOfCommonStock
Dividends paid: not filed

The data

The statements on this page as files, generated October 30, 2026.

JSON file
/data/financials/DXCM.json